Celularity

Home Company Newsroom Pipeline Products Celularity HOME COMPANY NEWSROOM PIPELINE PRODUCTS COVID-19 Update THE NEXT EVOLUTION IN CELLULAR MEDICINE Celularity is fundamentally altering how we approach the treatment of Cancer, Infectious Diseases, and Degenerative Diseases through continuous, innovative application of new discoveries in cellular medicine. COMPANY PIPELINE BEST IN CLASS & SCALABLE Cellular Medicine manufacturing Featuring industry leading and diverse product lines ALLOGENEIC PLATFORM Built on two decades of science Driven by a deep, seasoned management team INNOVATIVE PLACENTA-DERIVED T cells, NK Cells, and pluripotent stem cells With greater expandability, persistence, and stem-ness OUR MISSION is to lead the next evolution in cellular medicine by delivering off-the-shelf allogeneic cellular therapies, at unparalleled scale, quality, and economics stemcell_full OUR VISION Harness the Unique Biology & Ready Availability of the Placenta Unmet Global Need Significant unmet global need for allogeneic cellular medicines delivered on-demand, off-the-shelf Groundbreaking Research Groundbreaking basic & translational research into the unique biological activity of placental-derived cells Pioneering Technology Pioneering technology platform of placental-derived cellular medicines and advanced biomaterials Industry Timing The time has arrived for cellular medicines that overcome barriers of scale, quality, and economics Celularity ishyp| COMPANY PIPELINE CELLULAR MEDICINE MANUFACTURING The Process is the Product A fully integrated, purpose-built manufacturing, translational research and biobanking center Purpose built facility staffed by over 100 highly specialized scientists, engineers & technicians 150,000sq ft including laboratory and advanced manufacturing space for cellular medicine & biomaterials Clinical Scale – (9) Grade C/ISO 7 suites and (6) Grade D/ISO 8 labs ALL GMP-CAPABLE Check Out Our Virtual Tour THE LATEST FROM OUR NEWSROOM GX Acquisition Corp. Provides Information Regarding Extension of Deadline to Complete Celularity Business Combination GX Acquisition Corp. Provides Information Regarding Extension of Deadline to Complete Celularity Business Combination Celularity IncCelularity Inc Celularity Gains FDA Orphan Drug Status on Strength of Placental Stem Cell Trials Ankur K GargAnkur K Garg Celularity Receives Orphan Drug Designation for Natural Killer Cell Therapy CYNK-001 in the Treatment of Malignant Gliomas Celularity Receives Orphan Drug Designation for Natural Killer Cell Therapy CYNK-001 in the Treatment of Malignant Gliomas Celularity IncCelularity Inc Celularity Announces Multiple Presentations at the American Association for Cancer Research (AACR) Annual Meeting 2021 Celularity Announces Multiple Presentations at the American Association for Cancer Research (AACR) Annual Meeting 2021 Celularity IncCelularity Inc Celularity Inc. expansion is driven by experienced Cellular Medicine leaders & innovators with deep expertise in clinical development & regulatory approval. Meet Our Board of Directors celularity-horizontal-white (908) 768 - 2170 Directions Celularity Inc. 170 Park Ave Florham Park, NJ 07932 Science Placenta NK Cells T Cells Exosomes Biovance® Interfyl® Lifebank Collaborations Company Pipeline Our Story Leadership Scientific Advisors Board of Directors Collaborations Manufacturing Careers Copyright © 2021 Celularity Inc. All rights reserved Privacy Policy Terms & Conditions